[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495809":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"OncoHost Ltd.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-operable NSCLC patients receiving ICI therapy",null,"Patients with non-operable stage IIIB-IV NSCLC treated with immune check inhibitor anti cancer treatment as a standard of care",[13],"Other: blood, stool and tissue samples collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Operable NSCLC Patients Receiving ICI as Neoadjuvant or Adjuvant Therapy","Patients with operable stage II-IIIA NSCLC, treated with immune check inhibitor in the neoadjuvant or adjuvant setting",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy volunteers","Sex and aged matched non-diseased volunteers",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"OTHER","blood, stool and tissue samples collection","blood, stool and tissue samples collection before and during the treatment, as applicable",[19,9,15],[29],{"name":30,"affiliation":31,"role":32},"Ronan J Kelly, MD MBA","Chief of Oncology Baylor Scott & White Health System","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Galit Yahalom, PhD","CONTACT","97248537557","galit@oncohost.com",{"name":40,"role":36,"phone":37,"phoneExt":10,"email":41},"Shani Raveh Shoval, PhD","shani@oncohost.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Baylor Scott and White Research Institute","RECRUITING","Dallas","Texas","75204","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-96.80667,32.78306,{"lat":55,"lon":54},[58,61],{"name":59,"role":36,"phone":10,"phoneExt":10,"email":60},"Pappu Himabindu","Himabindu.Pappu@BSWHealth.org",{"name":30,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100495809","predicting-responsiveness-in-oncology-patients-based-on-host-response-evaluation-during-anti-cancer-treatments-using-multiomics-100495809",false,"NCT05736029","Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics","PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.","PROPHETIC","Inclusion Criteria:\n\n* Provision of informed consent prior to any study-specific procedures.\n* Male or female aged at least 18 years.\n* ECOG PS - 0\u002F1-2.\n\nExclusion Criteria:\n\n* Any concurrent and\u002For other active malignancy that has required systemic treatment within 2 years of first dose of treatment.\n* Generalized impairment or mental incompetence that would render the patient unable to understand his\u002Fher participation in the study.",true,"ALL","18 Years",{"count":76,"type":77},350,"ESTIMATED","OBSERVATIONAL","The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.\n\nThe investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment.\n\nPatients will provide biological samples before and during their treatment, and clinical data will be collected.",[81,82],"Non Small Cell Lung Cancer","Healthy","2023-02-09",{"date":85,"type":86},"2023-02-21","ACTUAL",{"date":88,"type":86},"2022-11-07",{"date":90,"type":77},"2028-06-30",{"name":5,"class":6},1]